Blog

Sep 11, 2023

An Immunotherapy Strategy Against All Blood Cancers

Posted by in categories: bioengineering, biotech/medical

In the study, published today in Science Translational Medicine, the researchers used engineered CAR T cells to target CD45—a surface marker found on nearly all blood cells, including nearly all blood cancer cells. Because CD45 is found on healthy blood cells too, the research team used CRISPR base-editing to develop a method called “epitope editing” to overcome the challenges of an anti-CD45 strategy, which would otherwise result in low blood counts, with potentially life-threating side effects. The early results represent a proof-of-concept for epitope editing, which involves changing a small piece of the target CD45 molecule just enough so that the CAR T cells don’t recognize it, but it… More.


A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. A new preclinical, proof-of-concept study details the “epitope-editing” approach.

Comments are closed.